Display Settings:

Format

Send to:

Choose Destination
Curr Pharm Des. 2012;18(22):3198-203.

Lenalidomide for treatment of myelodysplastic syndromes.

Author information

  • 1H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA. rami.komrokji@moffitt.org

Abstract

Lenalidomide is a second generation immunomodulatory agent (IMiD), which currently represents the standard of care for treatment of transfusion dependent lower risk myelodysplastic syndrome (MDS) patients with deletion (5q). Lenalidomide has unique activity with a high transfusion independence rate observed in this subset of patients. In this article we summarize the clinical experience using lenalidomide for treatment of del (5q) MDS. We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS.

PMID:
22571699
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk